Tepmetko OverviewTepotinib, sold under the brand name Tepmetko, is a medication for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. It is a c-Met inhibitor, a type of tyrosine kinase inhibitor. Tepotinib first received marketing approval in Japan, in March 2020, as a "line-agnostic" drug, meaning it is approved both for treatm...
Read more Tepmetko Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tepotinib
Recent Tepmetko Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet: 225mg
NDC Database Records for Tepmetko: (1 result)Sorted by National Drug Code
- 44087-5000 Tepmetko 225 mg Oral Tablet by Emd Serono, Inc.